FARMINGTON, Conn., Oct. 7, 2026 /PRNewswire/ -- Otis Worldwide Corporation (NYSE: OTIS) will host a conference call on Wednesday, October 28, 2026, at 8:30 a.m. ET. Otis Chair, CEO & President Judy Marks and Executive Vice President & CFO Cristina Mendez will discuss the company's third quarter results and 2026 outlook.

We encourage you to join through our webcast link. A corresponding presentation and news release will be available on www.otis.com prior to the call and a recording will be available on the website later in the day. If you are unable to join via the webcast, please contact Otis investor relations ([email protected]) for alternative dial-in information. Additional investor updates are also available on www.otis.com from time to time.

About Otis

Otis gives people freedom to connect and thrive in a taller, faster, smarter world. The global leader in the manufacture, installation, service and modernization of elevators and escalators, we move 2.5 billion people a day and maintain approximately 2.5 million customer units worldwide – the industry's largest Service portfolio. You'll find us in the world's most iconic structures, as well as residential and commercial buildings, transportation hubs and everywhere people are on the move. Headquartered in Connecticut, USA, Otis is 72,000 people strong, including 45,000 field professionals, all committed to manufacturing, installing and maintaining products to meet the diverse needs of our customers and passengers in more than 200 countries and territories. To learn more, visit www.otis.com and follow us on LinkedIn, YouTube, Instagram and Facebook @OtisElevatorCo.

Media Contact:

Katy Padgett

+1-860-674-3047

[email protected]

Investor Relations Contact:

Imelda Suit

+1-860-676-6011

[email protected] 

SOURCE Otis Worldwide Corporation

Share this article

TORONTO, Oct. 7, 2026 /PRNewswire/ -- Aclara Resources Inc. ("Aclara" or the "Company") (TSX: ARA) is pleased to announce the inauguration of a demonstration plant to develop the technology to produce rare earth metals and alloys. The demonstration plant was launched by Aclara Metals SpA ("Aclara Metals"), a 50/50 joint venture with CAP S.A. ("CAP"), focused on the development of rare earth metals and alloys production, and the technology draws on the metallurgical knowledge and experience accumulated over decades at CAP's Huachipato steelworks in Talcahuano. The start-up ceremony was attended by Sergio Giacaman, Governor of the Biobío Region, along with directors and executives of CAP, Aclara and Aclara Metals.

From left to right: Daniel Escobar, Biobío Regional Secretary of Mining (SEREMI); Christian Cifuentes, Biobío Regional Secretary of Economy, Development and Tourism (SEREMI); Álvaro Castellón, General Manager of Aclara Metals; Nicolás Burr, CEO of CAP; Ramón Barúa, CEO of Aclara; Jorge Salvatierra, Chairman of the Board of CAP; Sergio Giacaman, Governor of the Biobío Region; and Enrique Donoso, General Manager of Aclara Chile.

Using a molten salt electrolysis process, the demonstration plant will convert neodymium and praseodymium ("NdPr") oxides into metals and alloys. The facility is expected to validate this technology at industrial scale and under real operating conditions. It has been designed for a nominal production capacity of up to 175 kilograms of rare earth metal per day, with a target purity of at least 99.5%. Aclara Metals is also evaluating a second demonstration stage, following completion of the NdPr production stage, that would add dysprosium ("Dy") oxide to produce an NdPrDy alloy.

The demonstration plant will operate through production campaigns that are expected to validate its ability to produce metals and alloys under stable, continuous industrial conditions while meeting the quality specifications required by potential international customers. These campaigns are also expected to build operating experience and help train the teams involved in the future industrial facility.

Results based on real-world data from the demonstration plant are also expected to provide critical technical and operational inputs for the basic engineering for Aclara Metals' future industrial project in Louisiana, United States. This data will also be used to develop and refine predictive digital models that are aimed at optimizing the process and supporting a more stable and efficient operation of the electrolysis cells. The detailed design of the industrial-scale electrolysis cell has been developed entirely by teams from Aclara Metals and Huachipato and constitutes proprietary technology of the Company. With no established industrial standards for this metallurgical process to metallize rare earths, Aclara Metals' internally developed know-how represents a high-value technological asset.

Rare earth metals and alloys are essential inputs for manufacturing the permanent magnets used in electromobility, robotics, wind power generation, and other advanced technologies. The initiative will also generate knowledge in Chile that is expected to contribute to the development of new technologies key to the energy transition.

Toward an Integrated Value Chain

The initiative is part of Aclara and CAP's strategy to advance toward an integrated, traceable, and sustainable rare earth value chain, spanning extraction and separation through to the production of metals and alloys. In Chile, extraction will take place at the Penco Module, the country's first rare earth deposit.

Jorge Salvatierra, Chairman of the Board of CAP, said: "This plant is a concrete example of how the capabilities and knowledge developed over decades at Huachipato can be extended into new industries. We are combining metallurgical experience, infrastructure, and talent with new technological capabilities to innovate from Chile and to take part in a critical minerals value chain linked to the energy transition. It is also the kind of project we seek to drive as part of Huachipato's industrial transition, finding new uses for existing capabilities and opening space for knowledge- and innovation-intensive initiatives."

Ramón Barúa, CEO of Aclara, said: "This demonstration plant marks another important step in Aclara's development of an integrated rare earth supply chain. It complements our concentration pilot plants in Chile and Brazil and our separation pilot plant in Virginia, United States. With the addition of metallization and alloy production capabilities, Aclara is advancing toward an end-to-end technology and production platform integrating mining, concentration, separation, metallization, and alloy production. This completes a value chain that is critical to establishing a secure Western source of both heavy and light rare earths."

Álvaro Castellón, General Manager of Aclara Metals, added: "Rare earth metallization is a scarce, almost nonexistent technology in the West. This demonstration plant will allow us to replicate one of the four processes that make up metallization, generating concrete learnings that will complement the engineering work already underway as we advance toward a future industrial plant in the United States. Huachipato's metallurgical experience, together with the drive and conviction of CAP and Aclara, has created a unique combination that lets us move quickly and deliver concrete results."

About Aclara

Aclara Resources Inc. (TSX: ARA), a Toronto Stock Exchange listed company, is focused on building a vertically integrated supply chain for rare earth alloys used in permanent magnets, as well as high-purity rare earth oxides, including yttrium and gadolinium, for power generation, aerospace and other high-performance applications. This strategy is supported by Aclara's development of rare earth mineral resources hosted in ionic clay deposits, which contain high concentrations of the scarce heavy rare earths, providing the Company with a long-term, reliable source of these critical materials. The Company's rare earth mineral resource development projects include the Carina Project in the State of Goiás, Brazil as its flagship project and the Penco Module in the Biobío Region of Chile. Both projects feature Aclara's patented technology named Circular Mineral Harvesting, which offers a sustainable and energy-efficient extraction process for rare earths from ionic clay deposits. The Circular Mineral Harvesting process has been designed to minimize the water consumption and overall environmental impact through recycling and circular economy principles. Through its wholly-owned subsidiary, Aclara Technologies Inc., the Company is further enhancing its product value by developing a rare earth separation plant in the United States. This facility will process mixed rare earth carbonates sourced from Aclara's mineral resource projects, separating them into pure individual rare earth oxides. Additionally, Aclara through a joint venture with CAP, is advancing its alloy-making capabilities to convert these refined oxides into the alloys needed for fabricating permanent magnets. This joint venture leverages CAP's extensive expertise in metal refining and special ferro-alloyed steels. Beyond the Carina Project and the Penco Module, Aclara is committed to expanding its mineral resource portfolio by exploring greenfield opportunities and further developing projects within its existing concessions in Brazil, Chile, and Peru, aiming to increase future production of heavy rare earths.

Forward-Looking Statements

This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation and "forward-looking statements" within the meaning of applicable United States securities laws (together, "forward-looking information"). Forward-looking information includes, but is not limited to, statements regarding: the operation, nominal capacity, target purity and production campaigns of the demonstration plant; the ability of the demonstration plant to validate the technology and to meet customer specifications; a potential second demonstration stage involving dysprosium; the use of results and data from the demonstration plant in the basic engineering of Aclara Metals' future industrial project in Louisiana, United States, and in the development of predictive digital models; the development of the Penco Module and the receipt of environmental approvals; and the development of an integrated rare earth value chain. Forward-looking information is often, but not always, identified by words such as "expects", "anticipates", "plans", "intends", "targets", "evaluating", "will", "may", "could" and similar expressions.

Forward-looking information is based on assumptions that management believes to be reasonable, including that the demonstration plant will operate as designed; that the technology can be scaled up as anticipated; that required financing, permits and approvals will be obtained on acceptable terms and timelines; that Aclara and CAP will continue to support the objectives of Aclara Metals; and that market conditions for rare earth products will be favourable.

NORTHBROOK, Ill., Oct. 7, 2026 /PRNewswire/ -- Stepan Company (NYSE: SCL) will issue its third quarter 2026 earnings results on Wednesday, October 28, 2026 at approximately 7:00 a.m. ET (6:00 a.m. CT). Supporting slides will be posted at approximately the same time on the Investors/Presentations page at www.stepan.com. The Company will hold a conference call to discuss and answer questions about its financial and operational performance on the same day at 9:00 a.m. ET (8:00 a.m. CT).

The call will be hosted by Luis E. Rojo, President and Chief Executive Officer, and Ruben Velasquez, Senior Vice President and Chief Financial Officer.

The call can be accessed by phone and webcast. To access the call by phone, please click on this Registration Link, complete the form and you will be provided with dial in details and a PIN. To avoid delays, we encourage participants to dial into the conference call ten minutes ahead of the scheduled start time. The webcast can be accessed through the Investors/Conference Calls page at www.stepan.com. A webcast replay of the conference call will be available at the same location shortly after the call.

Corporate Profile

Stepan Company is a major manufacturer of specialty and intermediate chemicals used in a broad range of industries. Stepan is a leading merchant producer of surfactants, which are the key ingredients in consumer and industrial cleaning and disinfection products and in agricultural and oilfield solutions. The Company is also a leading supplier of polyurethane polyols used in the expanding thermal insulation market, and CASE (Coatings, Adhesives, Sealants, and Elastomers) industries.

Headquartered in Northbrook, Illinois, Stepan utilizes a network of modern production facilities located in North and South America, Europe and Asia.

The Company's common stock is traded on the New York Stock Exchange (NYSE) under the symbol SCL. For more information about Stepan Company please visit the Company online at www.stepan.com.

More information about Stepan's sustainability program can be found on the Sustainability page at www.stepan.com.

Certain information in this news release consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include statements about Stepan Company's plans, objectives, strategies, financial performance and outlook, trends, the amount and timing of future cash distributions, prospects or future events and involve known and unknown risks that are difficult to predict. As a result, Stepan Company's actual financial results, performance, achievements or prospects may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "guidance," "predict," "potential," "continue," "likely," "will," "would," "should," "illustrative" and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by Stepan Company and its management based on their knowledge and understanding of the business and industry, are inherently uncertain. These statements are not guarantees of future performance, and stockholders should not place undue reliance on forward-looking statements.

There are a number of risks, uncertainties and other important factors, many of which are beyond Stepan Company's control, that could cause actual results to differ materially from the forward-looking statements contained in this news release. Such risks, uncertainties and other important factors include, among other factors, the risks, uncertainties and factors described in Stepan Company's Form 10-K, Form 10-Q and Form 8-K reports and exhibits to those reports, and include (but are not limited to) risks and uncertainties related to accidents, unplanned production shutdowns or disruptions in manufacturing facilities; reduced demand due to customer product reformulations or new technologies; our inability to successfully develop or introduce new products; our ability to realize cost savings or operating efficiencies associated with strategic initiatives; compliance with laws; our ability to identify suitable acquisition candidates and successfully complete and integrate acquisitions; global competition; volatility of raw material and energy costs and supply; disruptions in transportation or significant changes in transportation costs; downturns in certain industries and general economic downturns; international business risks, including currency exchange rate fluctuations, legal restrictions and taxes; unfavorable resolution of litigation against us; maintaining and protecting intellectual property rights; our ability to access capital markets; global political, military, security or other instability; costs related to expansion or other capital projects; interruption or breaches of information technology systems; our ability to retain executive management and key personnel; and our debt covenants.

These forward-looking statements are made only as of the date hereof, and Stepan Company undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Stepan Company

Share this article

Abusix launches 'Abusix Frontline' to invest in long-term partner growth

Margin protection, pipeline incentives, and autonomy to drive partner growth.

BOSTON, Oct. 7, 2026 /PRNewswire/ -- Abusix today announced Abusix Frontline, a program giving partners commercial incentives, autonomy, and support via Authorized and Advanced tiers.

It offers deal registration, margin protection, pipeline incentives, and training. Partners retain standard margins on renewals and access to Abbie, an AI assistant for multilingual enablement.

Jasper Lounio, Head of Channel, said: "We've built this program around what makes a partner want to invest their time and resources in growing with Abusix. That means strong margins, protecting those margins when customers renew, and recognizing the work into creating pipeline, not just the final transaction."

Partners can register deals, create quotes, and progress opportunities independently, with zero channel conflict on registered accounts.

Tobias Knecht, Founder and CEO of Abusix, said: "Most phishing attacks travel through mail infrastructure offered by a service provider before it reaches anyone's inbox, and those operators know it. That is a problem our partners can sell into today. Partners bring the customer relationships and the local reach. We bring technology with proven demand, so the commercial opportunity is there from the first conversation."

Florent Manens, CEO at Beezim, added: "What we value about working with the Abusix Frontline program is the independence it gives us. We register an opportunity, create a quote, and progress the deal ourselves, while having direct access to the Abusix team. The service helps us provide the best quality filtering for our customers. Having everything in one place makes collaboration straightforward, lets us focus on our customers and growing the business."

Abusix Frontline is open to VARs, System Integrators, Technology partners, and Distributors. partners.abusix.com[email protected].

About Abusix

Abusix, a leading network security company that offers solutions for email security and network abuse report handling, is on a mission to build a safer internet. For network and mail providers, Abusix blocks email threats at the edge and automates network abuse handling from first report to resolution through its product suite: Abusix Mail, Abusix Ops, and Abusix Threat Intel. Seven of the ten largest European telecommunications companies are Abusix customers, alongside internet service providers, mailbox providers, and cloud and hosting companies across North America, EMEA, and APAC. Abusix Inc. is headquartered in Boston, Massachusetts. Learn more at abusix.com.

SOURCE Abusix Inc

Share this article

OpsGuru Named OpenAI Select Partner, Recognizing Its Work Bringing OpenAI Models to Enterprise AWS Environments

TORONTO, Oct. 7, 2026 /CNW/ -- OpsGuru, an AWS Premier Tier Services Partner, announced it has been named a registered OpenAI Select Partner. The designation recognizes what OpsGuru has already delivered in the field: agentic AI built on OpenAI models and running in production on AWS, often orchestrated through Amazon Bedrock, for enterprise customers in regulated industries.

"Our partnership with OpenAI represents the next chapter in OpsGuru's evolution, said Ryan Smyth, CEO of OpsGuru. "It brings together the best of what's next in AI with the data and cloud foundations our customers already trust, turning that innovation into real production outcomes."

The designation builds on OpsGuru's work delivering AI on AWS for enterprises in financial services, healthcare, retail, energy, and technology. Customers get a partner that designs, builds, and runs OpenAI-powered solutions within the security and governance standards they already operate under on AWS.

"It is an exciting time for OpsGuru, as we bring new ideas to life for our customers in unprecedented ways," said Tim Currie, President at OpsGuru. "We can move fast and innovate on OpenAI, but leverage the security and scale of AWS and Amazon Bedrock."

As an OpenAI Select Partner, OpsGuru will continue working closely with OpenAI to help organizations build, deploy, and scale AI solutions into production. This work will help organizations take advantage of the advanced capabilities and deeper reasoning of models like GPT-6 Astra to achieve new and exciting business outcomes.

"OpenAI continues to shape modern AI capabilities. We always engineer for security as a best practice, but integrating these platforms through Amazon Bedrock unites frontier model intelligence with secure, enterprise-grade cloud systems," said Mency Woo, Field CTO at OpsGuru. "Our teams at OpsGuru thrive at this intersection of high-level innovation, production-ready execution, and measurable outcomes and speed time-to-value."

OpsGuru customers keep the AWS and Amazon Bedrock teams they already trust, now with OpenAI's designation and support behind the work. That means getting AI into production faster, keeping costs under control, and scaling securely on one governed AWS foundation.

Enterprises ready to move OpenAI-powered AI from pilot to production on AWS can start a conversation with OpsGuru at opsguru.com or contact [email protected].

About OpsGuru

OpsGuru is a leading AWS Premier Tier Services Partner helping organizations of every size, from ambitious startups and growing SMBs to the world's largest enterprises, put AI at the core of how they operate. Holding the AWS Migration, DevOps, Networking, SaaS, and AI Services Competencies, along with the AWS Managed Service Provider Designation, OpsGuru brings deep technical expertise and proven delivery discipline to every engagement. OpsGuru designs, builds, and operates the cloud and AI systems that take organizations from proof of concept to production, securely and at scale, so businesses can move fast without slowing down for risk.

For further information, please contact:

Anita Matte

Senior Director, Marketing & Business Development

416-845-3235

[email protected]

SOURCE OpsGuru

Share this article

Three Scientists Honored with $250,000 Blavatnik Awards for Breakthroughs in Organic Chemistry, Gene Editing and Bioelectronics

News provided by

Blavatnik Family Foundation; The New York Academy of Sciences

Oct 07, 2026, 07:03 ET

Celebrations held at the American Museum of Natural History in New York for the Blavatnik Awards for Young Scientists' 20th anniversary gala.

NEW YORK, Oct. 7, 2026 /PRNewswire/ -- Three exceptional scientists each received $250,000 – the largest unrestricted scientific award available to early-career scientists in the United States – at the 2026 ceremony of the Blavatnik Awards for Young Scientists for their work in organic chemistry, genome engineering, and bioelectronics.

Presented by the Blavatnik Family Foundation and The New York Academy of Sciences, the Awards honor America's most innovative faculty-rank scientists and engineers, aged 42 and younger. The 2026 Laureates were selected from a highly competitive pool of 372 nominees representing 187 academic and research institutions across 43 states. From this national pool, an independent jury of eminent scientists also selected 15 Finalists who each received $15,000 in unrestricted funding.

The winners of the 2026 Blavatnik National Awards for Young Scientists are:

CHEMICAL SCIENCES LAUREATE:

David Nagib, The Ohio State University

Organic synthesis is a major bottleneck in the discovery of new medicines. To address this, organic chemist Prof. David Nagib develops methods to create key medicinal building blocks by harnessing reactive chemical species called radicals and carbenes. His lab has invented ways to activate inert portions of complex molecules. By turning high-energy chemistry into reliable methods, Nagib's work helps chemists create more potent and selective medicines faster, cheaper, and more efficiently. These advances are accelerating pharmaceutical discovery and expanding what is possible in modern organic chemistry.

LIFE SCIENCES LAUREATE:

Patrick Hsu, Arc Institute and Stanford University

Biology relies on molecular machines that read, write, and regulate genetic information, yet scientists are only beginning to understand how to harness their full potential. Prof. Patrick Hsu, a bioengineer and co-founder of the Arc Institute, discovers and engineers these programmable biological systems to precisely manipulate DNA and RNA. His work has expanded the CRISPR toolkit with RNA-targeting enzymes, uncovered programmable bridge RNAs that can direct large-scale genome rewriting, and pioneered artificial intelligence models that predict and design biological sequences. Together, these innovations are transforming genome engineering, accelerating biological discovery, and supporting the development of new gene therapies while laying the foundation for a new era of AI-enabled biological design.

PHYSICAL SCIENCES & ENGINEERING LAUREATE

Jonathan Rivnay, Northwestern University

The human body runs on chemical and ionic signals, but ordinary electronics struggle to read or join that conversation. To overcome this obstacle, materials scientist and biomedical engineer Prof. Jonathan Rivnay is designing soft, flexible electronic materials that work directly with living cells and tissue. Rivnay has helped to pioneer implantable "living pharmacies": small devices that hold engineered cells and prompt them to make and release medicines inside the body. Rivnay's work is leading the world to more personalized treatments for long-term conditions such as cancer, diabetes, and circadian rhythm disorders.

"We are extremely proud to recognize this year's National Laureates and to welcome them into the Blavatnik Awards community," said Len Blavatnik, Founder of Access Industries and Head of the Blavatnik Family Foundation.

The Ceremony

The Blavatnik Awards announced the Laureates at its 20th anniversary gala, a black-tie awards ceremony held October 6 at the American Museum of Natural History, hosted by Len and Emily Blavatnik and presented by Robert P. Lifton, MD, PhD, President of The Rockefeller University.

During the ceremony, each Laureate shared their prize-winning research with leading figures in philanthropy, research, academia, business, and the arts. Fifteen Blavatnik National Award Finalists and nine Blavatnik Regional Awards honorees were recognized as well.

This year also marked a milestone for two institutions: The Ohio State University and the Arc Institute each celebrated their first-ever Blavatnik National Award Laureates.

Reflecting on the long-term impact of the Awards, Lifton listed the successes of the first cohort of scientists who received their Blavatnik Award twenty years earlier. "From this inaugural group of 14 honorees, eight now hold named and endowed chairs at institutions including Yale, Rockefeller, Cornell, Columbia and Cambridge. Five have been elected to the U.S. National Academy of Sciences, two to the National Academy of Medicine, six to the American Academy of Arts & Sciences and one to the Royal Society of the UK. And subsequent to their Blavatnik Awards, they've won prizes such as the Shaw Prize, the Benjamin Franklin Medal and even the Fields Medal."

In his remarks, Professor Nicholas B. Dirks, President and CEO of The New York Academy of Sciences and Chair of the Awards' Scientific Advisory Council, recalled the origins of the Blavatnik Awards. The idea was inspired by Len Blavatnik's experience at the 2007 Nobel Prize ceremony, where the prestige of the occasion and the recognition of their lifelong discoveries prompted a question:

"What if exceptional scientists could be recognized earlier in their careers, at a pivotal moment when they were just beginning to build their own research programs, pursue ambitious scientific questions, and take creative risks? And so, twenty years ago, the Blavatnik Awards were born – a first-of-its-kind science prize dedicated to recognizing the most promising early-career scientists of their generation, administered by The New York Academy of Sciences."

Since 2007, the Blavatnik Awards have honored 539 scientists and awarded $21.5 million in unrestricted funding. At a time when intense competition for research funding makes it increasingly challenging for early-career scientists to establish independent programs and pursue innovative ideas, the Awards provide unrestricted prize funding that gives recipients the freedom to explore high-risk, high-reward research.

Beyond the lab, Blavatnik Awards honorees are using science to drive global economic growth. To date, Blavatnik Awards honorees have founded 52 companies, six of which are publicly traded, and collectively valued at more than $40 billion.

About the Blavatnik Awards for Young Scientists: blavatnikawards.org/about/

About the Blavatnik Family Foundation: blavatnikfoundation.org/about-us/

About The New York Academy of Sciences: nyas.org/about-us/

NOTE TO EDITORS: Select ceremony collateral, including imagery, videos, graphics, and headshots, can be found in the 2026 Blavatnik Awards Press Kit.

SOURCE Blavatnik Family Foundation; The New York Academy of Sciences

Share this article

Emerging Biotechs Standardize on Veeva Basics to Accelerate Drug Development

More than 175 biotechs use pre-configured applications to streamline operations

PLEASANTON, Calif., Oct. 7, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that more than 175 emerging biotechs are establishing a technology foundation with Veeva Basics. Biotechs are launching pre-configured and pre-validated Veeva Basics applications in weeks, adding systems that can scale as they move from startup to commercialization. Veeva Basics delivers unified, end-to-end applications for clinical, regulatory, quality, medical, and commercial, enabling high-growth companies to speed innovation while saving time, effort, and cost.

"As a growing company with under 40 employees, we're focused on developing science fast to deliver antibody-drug conjugates (ADCs) that target difficult-to-treat cancers," said Bryan Ball, chief technology operations officer at Whitehawk Therapeutics. "Our partnership with Veeva helped us replace paper processes with industry-leading solutions without an IT team or complex customizations. Veeva Basics redefined how we operate, significantly improving processes across regulatory and quality for greater speed and compliance."

Biotechs are leveraging Veeva Basics to drive new ways of working, including shifting regulatory publishing strategies from outsourced to insourced. Veeva Submissions Publishing Basics provides a modern application for submission building and health authority interactions that equips regulatory teams to bring publishing in-house. For biotechs preparing to publish their first submissions to the FDA, Veeva Basics enables them to hit critical regulatory milestones with improved visibility and control across the entire regulatory lifecycle.

"Insourcing our submission publishing through Veeva Basics gave us sharper quality control and significantly faster regulatory timelines," said Darryl Clarke, global head, regulatory operations at Structure Therapeutics. "We have modern applications with global support to execute quickly now, and the flexibility to scale in the future."

"Biotechs are responsible for so much of the innovation shaping the industry and they need technology that reflects the pace that they operate in," said Jim Thai, vice president, Veeva Basics. "It's been a privilege to work with industry pioneers and build this community of Veeva Basics customers advancing drug development."

Built on the proven Vault Platform, Veeva Basics applications help customers to scale their technology infrastructure seamlessly as they grow. For more on Veeva Basics, visit veevabasics.com, or register for Veeva R&D and Quality Summit, Oct. 20-21 in Boston. The event is open exclusively to life sciences industry professionals.

About Veeva Systems

Veeva delivers the industry cloud for life sciences with applications, agents, data, and consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva Forward-Looking Statements

This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the fiscal year ended July 31, 2026, which you can find here (a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at sec.gov.

Share this article

Nestlé and NBA announce multi-year international marketing partnership

- Milo,Nescau and Nesquikwill become Official Partners of the National Basketball Association (NBA)

- The partnership will include activations across select NBA youth basketball development programs and platforms

- Multi-year agreement spans 21 markets across four continents and marks Nestlé's largest international brand collaboration to date

VEVEY, Switzerland, Oct. 7, 2026 /PRNewswire/ -- Nestlé and the NBA are entering a new, multi‑year international marketing partnership making Milo, Nescau and Nesquik Official Partners of the NBA.

The agreement spans 21 markets across four continents and is designed to engage fans and inspire youth basketball participation around the world. Nestlé's largest international brand collaboration to date, the partnership reflects the company's strategy to focus on fewer, larger global marketing platforms that can be activated consistently across markets, ensuring local relevance. It will come into effect on 1 January 2027.

As part of the collaboration, Nestlé and the NBA will build on a shared commitment to youth participation in sport by creating more opportunities for young people and families to engage with basketball. This will include activations across select NBA youth basketball development programs and platforms, including Jr. NBA/Jr. WNBA, NBA Basketball School, Jr. NBA/Jr. WNBA Coaches Academies, Her Time To Play and NBA 3X, and will extend across select NBA events and fan engagement platforms, including NBA Global Games and NBA House.

"For decades, our brands have believed in the power of sport to bring out the best in people," said Liberato Milo, SVP Head of Confectionery & Snacking Strategic Business Unit at Nestlé. "From Milo and Nescau sports programs to Nesquik athlete partnerships and initiatives, we have seen how sport can energize people, build confidence and create healthy habits. Together with the NBA, we will use the power of basketball to connect with consumers at scale, create locally relevant experiences and inspire more young people and families to get active and enjoy the game."

The marketing partnership will also encompass retail programs and in-market fan experiences, including on-pack promotions featuring NBA branding and opportunities for consumers to win NBA tickets, merchandise and other prizes.

"Nestlé is one of the world's most recognizable brands and has a longstanding connection to consumers across the globe," said Julie Morris, NBA Senior Vice President of Commercial Development and Media. "We look forward to leveraging Nestlé's reach and local market presence to connect with fans in new ways and support the continued growth of basketball around the world."

The partnership will activate across: Australia, Brazil, Canada, Colombia, France, Germany, Ghana, Italy, Indonesia, Malaysia, Mexico, New Zealand, Nigeria, Singapore, Spain, Thailand, Turkey, the United Kingdom, the United States, Vietnam – with the Philippines joining from October 2027.

Contacts:

Nestlé: Chiara Valsangiacomo, +41 21 924 2200, [email protected]

NBA: Sam Postlethwaite, +44 7468 711407, [email protected]

Share this article

Company will measure autonomic and inflammatory signatures in up to 200 critically ill patients using its VITALx-patch wearable sensor and ARC cascade-endotyping classifier

LA JOLLA, Calif., Oct. 7, 2026 /PRNewswire/ -- InflammaSense, Inc., a pre-revenue medtech company developing wearable autonomic neurography (ANG) technology, today announced its selection as a performer on an Advanced Research Projects Agency for Health (ARPA-H) CIRCLE program receiving up to $38M to transform how clinicians track and treat critical illness in intensive care units. InflammaSense joins the program as a subaward performer under prime awardee the University of Vermont, working alongside UVM's Gary An on the ReSCUED effort within CIRCLE.

ARPA-H's CIRCLE program, short for Critical Illness Immunological Reprogramming and Control Point Learning Engine, targets the immune dysregulation that drives organ failure in critically ill patients; sepsis accounts for a substantial share of the roughly 4.6 million Americans who face potentially fatal critical illness each year. The program follows a measure-model-modulate framework: compiling real-time datasets on immune and inflammatory trajectories, building patient-specific computational models, and testing interventions that target immune control points before organ failure progresses.

Under the subaward, InflammaSense will deploy its VITALx-patch, a non-invasive wearable sensor, to measure autonomic and inflammatory signatures in up to 200 severely critically ill patients across three clinical sites. Data will feed the company's Autonomic Research Core (ARC) cascade-endotyping classifier, which stratifies patients by immune trajectory and supports the CIRCLE program's digital-twin modeling of critical illness. The work builds on InflammaSense's core platform; it was built on UC San Diego-owned intellectual property covering neural signal detection of immune responses through cervical Autonomic Neurography or "ANG" measured with ventral cervical or anterior neck magnetoneurography and electroneurography.

"CIRCLE gives us a path to validate ANG at scale in the population it was designed to serve," said Imanuel Lerman, MD, MSc, CEO and Founder of InflammaSense. "Sepsis hyperimmune and or immunoparalysis states are difficult to detect in real time with existing tools; this program will systematically determine whether continuous, non-invasive ANG monitoring can reliably flag that window early enough to act on it."

About InflammaSense, Inc.

InflammaSense is a pre-revenue medtech company based in La Jolla, California, developing autonomic neurography (ANG) technology for real-time immune monitoring. Its lead indication is sepsis immunoparalysis and sepsis hyperimmune states, paired with matched and targeted therapeutics.

Media Contact:

Imanuel Lerman 

InflammaSense, Inc.

[[email protected]] | [619-786-7202]

SOURCE InflammaSense

Share this article

MURFREESBORO, Tenn., Oct. 7, 2026 /PRNewswire/ -- National Health Investors, Inc. (NYSE:NHI) announced details for the release of its results for the third quarter ended September 30, 2026. NHI plans to issue its earnings release after the market closes on Monday, November 9, 2026, and will host a conference call on the following day, Tuesday, November 10, 2026, at 10:00 a.m. Eastern Time to discuss the results. The number to call for this interactive teleconference is (888) 506-0062, with the access code 260192.

The live broadcast of the conference call will be available online at www.nhireit.com and at https://www.webcaster5.com/Webcast/Page/633/54463 on Tuesday, November 10, 2026, at 10:00 a.m. Eastern Time. The online replay will be available shortly after the call and remain available for one year.

About National Health Investors, Inc.

National Health Investors, Inc. (NYSE:NHI), established in 1991, is a self-managed real estate investment trust specializing in sale-leaseback, joint venture, mortgage and mezzanine financing of need-driven and discretionary senior housing and medical facility investments. NHI operates in two reportable segments: Real Estate Investments and Senior Housing Operating Portfolio ("SHOP"). NHI's portfolio consists of independent living facilities, assisted living and memory care communities, entrance-fee retirement communities, senior living campuses, skilled nursing facilities and specialty hospitals. For more information, visit www.nhireit.com.

Contact: Dana Hambly, Senior Vice President, Finance

Phone: (615) 890-9100

SOURCE National Health Investors, Inc.

Share this article